Vaccine elicitation of HIV-1 neutralizing antibodies against both V2 apex and fusion peptide in rhesus macaques

Read full text
Authors: Hongying Duan, Joseph P. Nkolola, Shuishu Wang, Jayeshbhai Chaudhari, I‐Ting Teng, Christy L. Lavine, Danealle K. Parchment, G. J. Sellers, Krisha McKee, Sijy J. O’Dell, Misook Choe, Haijuan Du
+36 more Baoshan Zhang, Alejandro A. Espinosa Perez, Annika Rössler, Ninaad Lasrado, Andrea Biju, Jordan E. Becker, Robin Carroll, Audrey S. Carson, Amy R. Henry, Nicholas C. Morano, Madeeha Froze Mughal, Reda Rawi, Ryan S. Roark, Chaim A. Schramm, Chen‐Hsiang Shen, Sarah Jane Smith, Tyler Stephens, Yaroslav Tsybovsky, David J. Van Wazer, Hua Wang, Yongping Yang, Lucy Rutten, Johannes P.M. Langedijk, Cheng Cheng, Lingshu Wang, Daniel C. Douek, Richard A. Koup, John R. Mascola, Lawrence Shapiro, Tongqing Zhou, Nicole A. Doria-Rose, Bette Korber, Michael S. Seaman, Theodore C. Pierson, Peter D. Kwong, Dan H. Barouch
Cited by: 1
References: 64

Abstract

Broadly neutralizing antibodies (bNAbs) targeting multiple sites of HIV-1 Env vulnerability can be induced by infection, but simultaneous elicitation of bNAbs against multiple epitopes has not been achieved by vaccination. In this study, we designed a dual-epitope vaccine targeting both the fusion peptide (FP) and the V2 apex and evaluated its capacity to induce bNAbs against both epitopes in rhesus macaques. This vaccine combined an FP conjugate with a cocktail of engineered Env trimers with enhanced V2 apex recognition and increased antigen retention in lymph nodes. Macaque immunization with the dual-epitope vaccine elicited >1,000-fold higher autologous tier 2-neutralizing titers than wild-type Env trimers and enhanced heterologous neutralization. Both FP- and V2 apex-monoclonal antibodies were isolated from immunized macaques and showed heterologous neutralization with genetic and structural signatures similar to well-characterized FP and V2 apex bNAbs. These results demonstrate proof of concept for simultaneous vaccine elicitation of neutralizing antibodies against multiple sites of Env vulnerability.

Fields of Study & Subjects

HIV Research and Treatment HIV/AIDS drug development and treatment HIV/AIDS Research and Interventions

Publication details

Journal / source
Cell Reports
Publisher
Elsevier BV
Volume
45
Issue
2
Pages
116905–116905
Publication date
29 January 2026
Language
EN